These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 11297243)

  • 1. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin.
    Takahashi N; Kawanishi-Tabata R; Haba A; Tabata M; Haruta Y; Tsai H; Seon BK
    Clin Cancer Res; 2001 Mar; 7(3):524-32. PubMed ID: 11297243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
    Takahashi N; Haba A; Matsuno F; Seon BK
    Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis and metastasis marker of human tumors.
    Seon BK; Takahashi N; Haba A; Matsuno F; Haruta Y; She XW; Harada N; Tsai H
    Rinsho Byori; 2001 Oct; 49(10):1005-13. PubMed ID: 11769465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies.
    Matsuno F; Haruta Y; Kondo M; Tsai H; Barcos M; Seon BK
    Clin Cancer Res; 1999 Feb; 5(2):371-82. PubMed ID: 10037187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
    Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
    Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1998; 18(5A):3621-8. PubMed ID: 9858949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1998; 18(3A):1485-500. PubMed ID: 9673360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1998; 18(4A):2701-10. PubMed ID: 9703932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.
    She X; Matsuno F; Harada N; Tsai H; Seon BK
    Int J Cancer; 2004 Jan; 108(2):251-7. PubMed ID: 14639611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature.
    Uneda S; Toi H; Tsujie T; Tsujie M; Harada N; Tsai H; Seon BK
    Int J Cancer; 2009 Sep; 125(6):1446-53. PubMed ID: 19533687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers].
    Charpin-Taranger C; Dales JP; Garcia S; Andrac-Meyer L; Ramuz O; Carpentier-Meunier S; Bonnier P
    Bull Acad Natl Med; 2003; 187(6):1129-45; discussion 1145-6. PubMed ID: 14978873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis.
    Li C; Gardy R; Seon BK; Duff SE; Abdalla S; Renehan A; O'Dwyer ST; Haboubi N; Kumar S
    Br J Cancer; 2003 May; 88(9):1424-31. PubMed ID: 12778073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy.
    Burrows FJ; Derbyshire EJ; Tazzari PL; Amlot P; Gazdar AF; King SW; Letarte M; Vitetta ES; Thorpe PE
    Clin Cancer Res; 1995 Dec; 1(12):1623-34. PubMed ID: 9815965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites.
    Tsujie M; Uneda S; Tsai H; Seon BK
    Int J Oncol; 2006 Nov; 29(5):1087-94. PubMed ID: 17016638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105).
    Toi H; Tsujie M; Haruta Y; Fujita K; Duzen J; Seon BK
    Int J Cancer; 2015 Jan; 136(2):452-61. PubMed ID: 24866768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count.
    Romani AA; Borghetti AF; Del Rio P; Sianesi M; Soliani P
    J Surg Oncol; 2006 May; 93(6):446-55. PubMed ID: 16615157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model.
    Fonsatti E; Jekunen AP; Kairemo KJ; Coral S; Snellman M; Nicotra MR; Natali PG; Altomonte M; Maio M
    Clin Cancer Res; 2000 May; 6(5):2037-43. PubMed ID: 10815930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD105 is important for angiogenesis: evidence and potential applications.
    Duff SE; Li C; Garland JM; Kumar S
    FASEB J; 2003 Jun; 17(9):984-92. PubMed ID: 12773481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.
    Gluz O; Wild P; Liedtke C; Kates R; Mendrik H; Ehm E; Artinger V; Diallo-Danebrock R; Ting E; Mohrmann S; Poremba C; Harbeck N; Nitz U; Hartmann A; Gaumann A
    Breast Cancer Res Treat; 2011 Apr; 126(3):643-51. PubMed ID: 21318601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer.
    Coskun U; Günel N; Toruner FB; Sancak B; Onuk E; Bayram O; Cengiz O; Yilmaz E; Elbeg S; Ozkan S
    Neoplasma; 2003; 50(1):41-6. PubMed ID: 12687277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.